Victor Matthews, MD
Endocrinology, Diabetes & Metabolism · Winter Garden, FLNPI 1457363541
Payments from drug & device makers
Across 118 payments — averaging $68.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tandem Diabetes Care, Inc.$5K
- Novo Nordisk$311
- Sanofi-aventis U.S. LLC$284
- Amgen$249
- Bayer$207
- Cequr Corporation$199
- plus $1K from 27 others
What the payments were for
- Speaking & faculty fees$5,30065%
- Food & beverage$2,79935%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Tandem Diabetes Care, Inc. | 23 | $5,456 |
| Novo Nordisk | 8 | $311 |
| Sanofi-aventis U.S. LLC | 5 | $284 |
| Amgen | 14 | $249 |
| Bayer | 7 | $207 |
| Cequr Corporation | 1 | $199 |
| Verity Pharmaceuticals Inc. | 2 | $177 |
| Lilly USA, LLC | 10 | $172 |
| Insulet Corporation | 5 | $148 |
| Ascensia Diabetes Care US Inc. | 5 | $123 |
| Xeris Pharmaceuticals, Inc. | 4 | $78 |
| Boehringer Ingelheim | 4 | $72 |
| Medtronic | 2 | $71 |
| Merck | 4 | $66 |
| AstraZeneca | 3 | $53 |
| Sequel Med Tech, LLC | 2 | $48 |
| Shire North American Group Inc | 2 | $40 |
| Recordati_rare_diseases_inc. | 1 | $38 |
| Amarin Pharma, Inc. | 2 | $33 |
| Neurocrine Biosciences, Inc. | 1 | $29 |
| Amneal Pharmaceuticals LLC | 1 | $25 |
| Novartis | 1 | $24 |
| Ascendis Pharma Endocrinology Inc | 1 | $24 |
| Esperion Therapeutics, Inc. | 1 | $22 |
| Acella Pharmaceuticals, LLC | 1 | $21 |
| Corcept Therapeutics | 1 | $21 |
| Kyowa Kirin, Inc. | 1 | $20 |
| Antares Pharma, Inc. | 1 | $20 |
| Valeritas, Inc. | 1 | $20 |
| BETA Bionics, Inc. | 1 | $17 |
| Johnson & Johnson | 1 | $15 |
| Madrigal Pharmaceuticals | 1 | $15 |
| Dexcom, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- t-slim insulin pump$5,300
- SOLIQUA 100/33$215
- CeQur Simplicity$199
- TLANDO$162
- Kerendia$116
- Ozempic$108
How this compares
$8,111 in reported general payments places this provider in the 60th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
See all endocrinology, diabetes & metabolism providers in Florida →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 193 | $235,521 |
| Tresiba Flextouch U-100Insulin Degludec | 210 | $219,395 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 73 | $113,205 |
| JardianceEmpagliflozin | 80 | $99,932 |
| MounjaroTirzepatide | 47 | $61,638 |
| GlyxambiEmpagliflozin/Linagliptin | 59 | $56,405 |
| TrulicityDulaglutide | 27 | $52,049 |
| Tresiba Flextouch U-200Insulin Degludec | 16 | $40,861 |
| RybelsusSemaglutide | 17 | $38,260 |
| Repatha SureclickEvolocumab | 38 | $36,380 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 24 | $33,812 |
| FarxigaDapagliflozin Propanediol | 32 | $31,292 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 16 | $21,918 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 31 | $18,086 |
| Novolog FlexpenInsulin Aspart | 48 | $17,907 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Tresiba, Novolog | $311 | $292,926246 claims |
| Boehringer IngelheimJardiance, Glyxambi, Trijardy Xr, Synjardy Xr | $72 | $212,066179 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $172 | $120,161104 claims |
| AstraZenecaFarxiga | $53 | $31,29232 claims |
| BayerKerendia | $207 | $6,78811 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $25 | $4,066281 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
Other endocrinology, diabetes & metabolism in Winter Garden
- Richard PratleyOrlando$9.2M
- Jose MandryOcoee$9.1M
- Steven SmithOrlando$7.9M
- Barry HorowitzWest Palm Beach$7.1M
- Tina ThethiOrlando$3.8M
- David SuttonJacksonville$3.1M
- Lorena Lewy-AlterbaumHollywood$3.1M
- Mae Sheikh AliJacksonville$2.9M
- James MageeJacksonville$2.7M
- Rodolfo GalindoMiami$2.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.